Abstract

Chronic liver disease is becoming more common in the UK. There has been much media coverage due to recent change in licensing laws and celebrity figures suffering from cirrhosis. This review highlights the common complications of cirrhosis that frequently present to the acute physician, focussing on initial presentation and subsequent management, based on the current best available evidence.
[download-attachments container="div" style="list" dipslay_icon="1" display_count="1" display__size="0"]

References

1. Bellentani S, Tiribelli C, Saccoccio G, et al. Prevalence of chronic liver disease in the general population of Northern Italy: the Dionysos Study. Hepatology 1994; 20 (6): 1442-9.
2. Austin M, Bernal W, Auzinger G, et al. Assessment of prognosis of prognosis in critically ill adult patients with chronic liver disease requiring intensive care admission. A single centre experience of 363 patients (abstract).BASL 2005.
3. Saunders J and Latt N. Epidemiology of alcoholic liver disease. Balliere’s Clinical gastroenterology 1993; 7:55-84.
4. Anderson P. Excess mortality associated with alcohol consumption. Br Med J 1988; 297:824-6.
5. Mathurin P, Duchatelle V, Ramond MJ, et al. survival and prognostic factors in patients with severe alcoholic hepatitis treated with prednisolone. Gastroenterology 1996; 110:1847-53.
6. Haber PS, Warner R, Seth D, et al. Pathogenesis and management of alcoholic hepatitis. J Gastro Hep 2003; 18:1332-1344.
7. Ramond MJ, et al. A randomized trial of prednisolone in patients with severe alcoholic hepatitis. N Eng J Med 1992; 326:507-12.
8. Mendenhall WC, et al. Short term and long term survival in patients with alcoholic hepatitis treated with oxandrolone and prednisolone. N Eng J Med 1984; 311:1464-70.
9. Forrest EH, Evans CDJ, Stewart S, et al. Analysis of factors predictive of mortality in alcoholic hepatitis and derivation and validation of the Glasgow alcoholic hepatitis score. Gut 2005; 54:1174-1179.
10. Thompson AD, et al. The Royal College of Physicians’ Report on Alcohol: guidelines for managing Wernicke’s encephalopathy in the accident and emergency department. Alcohol Alcohol 2002; 37:513-21.
11. Mathurin P. Corticosteroids for alcoholic hepatitis –what’s next? J Hep 2005; 43: 526-533.
12. Akriviadis E, Botla R, Briggs W, et al. Pentoxifylline improves short term survival in severe acute alcoholic hepatitis. Gastroenterology 2000; 119: 1637-48.
13. Gines P, Arroyo V, Quintero E, et al. Comparison of paracentesis and diuretics in the treatment of cirrhotics with tense ascites. Gastroenterology 1987; 93:234-241.
14. Gines P, Tito L, Arroyo V, et al. Randomized comparative study of therapeutic paracentesis with and without intravenous albumin in cirrhosis. Gastroenterology 1988; 94:1493-1502.
15. Sola-Vera J, Minana J, Ricart E, et al. Randomized trial comparing albumin and saline in prevention of paracentesis induced circulatory dysfunction in cirrhotic patients with ascites. Hepatology 2003; 37: 1147-1153.
16. Moreau R, Asseiah T, Condat B, et al. Comparison of the effect of terlipressin and albumin on arterial blood volume in patients with cirrhosis and tense ascites treated by paracentesis: a randomised pilot study. Gut 2002; 50: 90-94.
17. Wong F, Bernardi M, Balk R, et al. Sepsis in cirrhosis: report on the 7th meeting of the International Ascites Club. Gut 2005; 54:718-725.
18. Sort P, Navasa M, Arroyo V, et al. Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis. N Eng J Med 1999; 341: 403-9.
19. Angeli P. Review article: prognosis of hepatorenal syndrome – has it changed with current practice. Aliment Pharm Ther 2004; 20(suppl.3):44-46.
20. Arroyo V, Gines P, Gerbes A, et al. Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome. Hepatology 1996; 23:164-176
21. Ortega R, Gines P, Uriz J, et al. Terlipressin therapy with or without albumin for patients with hepatorenal syndrome: results of a prospective non randomized study. Hepatology 2002; 36:941-948.
22. Uriz J, Gines P, Cardenas A, et al. Terlipressin plus albumin infusion: an effective and safe therapy of hepatorenal syndrome. J Hepatol 2000; 33:43-48
23. Duvoux C, Zanditenas D, Hezode C, et al. Effects of noradrenaline and albumin in patients with type 1 hepatorenal syndrome: a pilot study. Hepatology 2002; 36:374-380.
24. Angeli P, Volpin R, Gerunda G, et al. Reversal of type 1 hepatorenal syndrome with the administration of midodrine and octreotide. Hepatology 1999; 29:1690-1697.
25. Wong F, Pantea L, Sniderman K. Midodrine, octreotide, albumin and TIPS in selected patients with cirrhosis and type 1 hepatorenal syndrome. Hepatology 2004; 40:55-64.
26. Cardenas A. Hepatorenal syndrome: A dreaded complication of end stage liver disease. Am J of Gastroenterology 2005; 100: 460-467.
27. Gines P, Guevara M, Arroyo V and Rodes J. Hepatorenal syndrome. Lancet 2003; 362: 1819-27.
28. Blei AT, Cordoba J. Hepatic encephalopathy. Am J Gastro 2001; 6(7): 1968-76.
29. Atterbury CE, Maddrey WC, Conn HO. Neomycin-sorbitol and lactulose in the treatment of acute portal-systemic encephalopathy. A controlled, double blind clinical trial. Am J Dig Dis 1978; 23: 398-406.
30. Riggio O, merdi M, Capocaccia L, et al. Zinc supplementation reduces blood ammonia and increases liver ornithine transcarbamylase activity in experimental cirrhosis. Hepatology 1992; 16: 785-789.
31. Als-Nielsen B, Gluud C and Gluud LL. Non absorbable disaccharides for hepatic encephalopathy. Cochrane Database Systematic Review 2004; 2: CD003044.
32. Cardenas A, Kelleher T and Chopra S. Review article: hepatic hydrothorax. Aliment Pharmacol Ther 2004; 20: 271-279.